| Clinical features of an anti-anginal drug in angina pectoris. | |
| | |
MedLine Citation:
|
PMID: 7904559 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Trimetazidine (TMZ) exerts anti-ischaemic effects without any associated central haemodynamic change, both at rest and with exercise. These findings suggest that TMZ has a direct cytoprotective effect, the efficacy of which has been confirmed by clinical studies in effort angina. TMZ as monotherapy when compared with placebo, in acute (60 mg) as well as in chronic (20 mg t.i.d.) administration, significantly improves exercise tolerance: total work, duration of exercise and time to 1 mm ST segment depression, without changing the rate-pressure product. Moreover, during chronic treatment TMZ decreases the rate of anginal attacks. In patients with coronary heart disease insufficiently controlled with nifedipine or a beta-blocker as monotherapy, the addition of TMZ (20 mg t.i.d.) significantly reduces the number of anginal attacks and improves exercise capacity. TMZ antianginal activity in monotherapy has also been compared in double-blind controlled studies with that of a calcium channel antagonist and a beta-blocker as reference drugs. TMZ is as efficient as nifedipine or propranolol on clinical variables as well as on ergometric criteria, but unlike these two reference drugs, which act through a haemodynamic mechanism, TMZ does not decrease rate-pressure product. Furthermore, in the study comparing TMZ with propranolol, TMZ was shown to decrease ischaemic episodes recorded by ECG ambulatory monitoring. These data show that TMZ belongs to the major antianginal agents available today. However, the absence of central haemodynamic effects suggests that the drug has a novel anti-ischaemic mechanism involving direct myocardial cytoprotection. |
| | |
Authors:
|
J M Detry |
Related Documents
:
|
332439 - Trials with an adenosine analogue as antianginal medication. 6775619 - Prostacyclin for acute coronary insufficiency. 9475269 - Short- and long-term effects of molsidomine retard and molsidomine nonretard on exercis... 7925519 - Duration and extent of antianginal effects of a sustained-release formulation of nifedi... 3348139 - Increased exercise tolerance and reduced duration of ischemia after isosorbide dinitrat... 2871779 - The use of beta-adrenergic blockers in the treatment of angina and hypertension. 7579049 - Exercise-induced acute renal failure associated with ibuprofen, hydrochlorothiazide, an... 15818199 - Long-term effects of cardiac rehabilitation and the paradigms of cardiac rehabilitation. 17653139 - Endothelium-mediated modulation of ergoreflex and improvement in exercise ventilation b... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: European heart journal Volume: 14 Suppl G ISSN: 0195-668X ISO Abbreviation: Eur. Heart J. Publication Date: 1993 Nov |
Date Detail:
|
Created Date: 1994-02-24 Completed Date: 1994-02-24 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8006263 Medline TA: Eur Heart J Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 18-24 Citation Subset: IM |
Affiliation:
|
Département de Médecine Interne, Université Catholique de Louvain, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenergic beta-Antagonists
/
therapeutic use Angina Pectoris / drug therapy* Calcium Channel Blockers / therapeutic use Clinical Trials as Topic Drug Therapy, Combination Humans Male Middle Aged Nifedipine / therapeutic use Trimetazidine / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic beta-Antagonists; 0/Calcium Channel Blockers; 21829-25-4/Nifedipine; 5011-34-7/Trimetazidine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Delta-crystallin enhancer binding protein delta EF1 is a zinc finger-homeodomain protein implicated ...
Next Document: Metabolic management of ischaemic heart disease.